Contribute Try STAT+ Today

Douglas Fambrough III had good news about his fledgling biotech company when he met with a roomful of investment analysts in a swanky midtown Manhattan hotel on a November morning in 2014.

During a half-hour presentation at the Lotte New York Palace, the chief executive of Dicerna Pharmaceuticals Inc. showed 19 slides that gave an overview of his Watertown, Mass., firm. The 11th one featured a diagram with circles and squiggly lines. It represented a new delivery system for gene-silencing drugs that Dicerna hoped to develop to treat rare disorders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.